Showing results (11-20 of 47) with videos related to
Sort By:
Pageof 5
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 3, 2009
Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projectionsAberra Fura, Ashish Khanna, Viral Vyas, et al.The Lancet. Rheumatology|May 4, 2026
Efficacy and safety of branebrutinib (BMS-986195), an irreversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2a, randomised, double-blind, placebo-controlled studyMikkel Østergaard, Espen A Haavardsholm, Miroslawa Nowak, et al.Bioorganic & Medicinal Chemistry Letters|February 17, 2005
Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitorsRobert M Borzilleri, Zhen-Wei Cai, Christopher Ellis, et al.Bioorganic & Medicinal Chemistry Letters|October 15, 2011
7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active siteWei Wang, Pratik Devasthale, Aiying Wang, et al.Plos One|July 26, 2017
Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-careKathleen M Gillooly, Claudine Pulicicchio, Mark A Pattoli, et al.Bioorganic & Medicinal Chemistry Letters|August 28, 2022
The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancerChetan Padmakar Darne, Upender Velaparthi, Mark Saulnier, et al.Journal of Medicinal Chemistry|January 7, 2026
Enhancing the Oral Bioavailability of a Poorly Soluble Pan-CK2 Kinase Inhibitor: Leveraging a Phosphate Prodrug Strategy to Overcome Dissolution-Limited Absorption and Improve Systemic Exposure during Dose EscalationMurugaiah A M Subbaiah, Naveen Manjunath, Thangeswaran Ramar, et al.Journal of Medicinal Chemistry|June 10, 2005
Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitorsRobert M Borzilleri, Xiaoping Zheng, Ligang Qian, et al.Journal of Medicinal Chemistry|August 6, 2010
Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitorsWei Meng, Robert P Brigance, Hannguang J Chao, et al.Journal of Medicinal Chemistry|June 8, 2026
Drug Delivery Strategy Exploiting Amino Acid Prodrugs: Improving Oral Bioavailability and Overcoming Nonlinear Pharmacokinetic Challenges Following Dose Escalation of a CK2 Inhibitor with Poor SolubilityMurugaiah A M Subbaiah, Thangeswaran Ramar, Mathiazhagan Annadurai, et al.Pageof 5